Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PMN

STRONG SELLREMOVE

ProMIS Neurosciences, Inc. · Healthcare · Canada · $97M · Avg Vol: $190K/d

15
StockRank
Q
21
V
32
M
45
P/E (TTM)
ROE
-115.7%
D/E
Dividend %
AI CONVICTION THESIS

A micro-cap biotech focused on neurodegenerative diseases with high cash burn, binary clinical risks, and no commercial revenues.

COMPANY DESCRIPTION

ProMIS Neurosciences, Inc. is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. The company utilizes its proprietary discovery platform to identify toxic conformers of misfolded proteins as drug targets. Its competitive moat is its unique approach to targeting specific disease-causing protein structures, aiming for highly selective and effective treatments.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue0000
EPS-2.31-2.250.39-5.43
Shares9.0M9.0M9.0M9.0M0.0%
Debt3.9M8.3M9.9M2.4M10.4M27.9%
Equity-1.3M3.8M16.5M-1.3M339.3%
Op CF-17.0M-10.8M-27.2M-28.1M
Inv CF-1,981-1,349-693-702
Fin CF6.5M17.7M27.9M20.9M
Loading...
PRICE (1Y)-3.0%
9.139.5910.0510.5210.98May 13Jun 4Jun 25
SMA 50SMA 200
Close
$10.25
RSI (14)
56.6
52W High
$39.75
From 52W High
0.3%

SCORE BREAKDOWN

Quality
21
ROIC (ROA)
-63.0%*10.5
ROE
-115.7%6.8
GP/Assets
-363.5%0.1
Op. Margin
0.0%40.6
FCF/Assets
-204.9%0.4
Piotroski
212.0
Int. Cover
N/A
D/E Ratio
N/A
Current Ratio
9.92x86.8
Value
32
P/E (TTM)
N/A
EV/EBITDA
N/A
P/FCF
N/A
P/B
1.6x68.3
P/S
N/A
Div Yield
N/A
Momentum
45
52W High %
26%4.6
RS 6M
18%82.3
SMA 50/200
0.91x38.7
EPS Rev 4W
0.0%49.3
EPS Rev 12W
+94.1%95.7
EPS Improve
+97%71.4
Q Growth
N/A

FUNDAMENTALS

Market Cap
$97M
P/E (Forward)
-17.5x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PMN are excluded.

TickerCompanyMkt CapStockRankSignal
PMNProMIS Neurosciences, Inc.(you)$97M15STRONG SELL
OBI.LOndine Biomedical Inc.$101M20SELL
MSLESatellos Bioscience Inc.$119M10STRONG SELL
ENGNenGene Therapeutics Inc.$114M8STRONG SELL
EDSAEdesa Biotech, Inc.$61M17STRONG SELL
MISTMilestone Pharmaceuticals Inc.$161M1STRONG SELL
HELPCybin D/B/A Helus Pharma$245M6STRONG SELL
QNTM.CNQuantum BioPharma Ltd.$45M2STRONG SELL
NGENNervGen Pharma Corp.$244M1STRONG SELL
TELI.CNTelescope Innovations Corp.$49M40HOLD

Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%

ProMIS Neurosciences, Inc. (PMN) — Stock Score Summary

ProMIS Neurosciences, Inc. (PMN) has a MoatMap StockRank of 15/100 based on Quality (21/100), Value (32/100), and Momentum (45/100) factor scores. The current signal is STRONG SELL. A micro-cap biotech focused on neurodegenerative diseases with high cash burn, binary clinical risks, and no commercial revenues.

ProMIS Neurosciences, Inc. is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. The company utilizes its proprietary discovery platform to identify toxic conformers of misfolded proteins as drug targets. Its competitive moat is its unique approach to targeting specific disease-causing protein structures, aiming for highly selective and effective treatments.

Key Financial Metrics

Price$10.25
Market Cap$97M
P/E (Forward)-17.50
Price/Book1.58
Return on Equity-115.7%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-19M

ProMIS Neurosciences, Inc. operates in the Biotechnology industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is ProMIS Neurosciences, Inc.’s (PMN) StockRank?
MoatMap’s StockRank for ProMIS Neurosciences, Inc. (PMN) is 15/100, with a Strong Sell signal. It is a composite of Quality (21), Value (32), and Momentum (45) factor ranks across MoatMap’s 20,000+ stock universe.
Does ProMIS Neurosciences, Inc. have an economic moat?
ProMIS Neurosciences, Inc. (PMN) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ProMIS Neurosciences, Inc. a buy, hold, or sell?
MoatMap’s current signal for ProMIS Neurosciences, Inc. (PMN) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is ProMIS Neurosciences, Inc. in?
ProMIS Neurosciences, Inc. (PMN) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).